CL2024001431A1 - Compuestos para tratar anemias asociadas a mds y otras afecciones - Google Patents

Compuestos para tratar anemias asociadas a mds y otras afecciones

Info

Publication number
CL2024001431A1
CL2024001431A1 CL2024001431A CL2024001431A CL2024001431A1 CL 2024001431 A1 CL2024001431 A1 CL 2024001431A1 CL 2024001431 A CL2024001431 A CL 2024001431A CL 2024001431 A CL2024001431 A CL 2024001431A CL 2024001431 A1 CL2024001431 A1 CL 2024001431A1
Authority
CL
Chile
Prior art keywords
mds
conditions
compounds
anemia associated
treat anemia
Prior art date
Application number
CL2024001431A
Other languages
English (en)
Spanish (es)
Inventor
Beynon Vanessa
Joy Bhatia Suman
Dang Lenny
L Dibacco Melissa
V Iyer Varsha
Kung Charles
Lynch Megan
Qiping Yin Ophelia
Urbstonaitis Rolandas
Xiao Zhen
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of CL2024001431A1 publication Critical patent/CL2024001431A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CL2024001431A 2021-11-16 2024-05-14 Compuestos para tratar anemias asociadas a mds y otras afecciones CL2024001431A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163280069P 2021-11-16 2021-11-16
US202263357240P 2022-06-30 2022-06-30

Publications (1)

Publication Number Publication Date
CL2024001431A1 true CL2024001431A1 (es) 2024-10-25

Family

ID=84887868

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024001431A CL2024001431A1 (es) 2021-11-16 2024-05-14 Compuestos para tratar anemias asociadas a mds y otras afecciones

Country Status (11)

Country Link
US (1) US20250108049A1 (cg-RX-API-DMAC7.html)
EP (1) EP4433057A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543345A (cg-RX-API-DMAC7.html)
KR (1) KR20240107326A (cg-RX-API-DMAC7.html)
AU (1) AU2022390088B2 (cg-RX-API-DMAC7.html)
CA (1) CA3236880A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001431A1 (cg-RX-API-DMAC7.html)
IL (1) IL312679A (cg-RX-API-DMAC7.html)
MX (1) MX2024005852A (cg-RX-API-DMAC7.html)
TW (1) TW202329935A (cg-RX-API-DMAC7.html)
WO (1) WO2023091414A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024238659A1 (en) * 2023-05-15 2024-11-21 Agios Pharmaceuticals, Inc. Crystalline salts or amorphous forms of 2-((1h-pyrazol-3-yl)methyl)-6-((6-aminopyridin-2-yl)methyl)-4-methyl-4,6-dihydro -5h-thiazolo[5',4':4,5]pyrrolo[2,3-d]pyridazin-5-one
WO2026076363A1 (en) 2024-10-04 2026-04-09 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
MX384883B (es) 2015-06-11 2025-03-14 Agios Pharmaceuticals Inc Métodos para usar activadores de piruvato cinasa.
EP3668513B1 (en) 2017-08-15 2021-11-10 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in treating blood disorders
KR102682430B1 (ko) 2017-11-22 2024-07-08 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태
JP2022533227A (ja) 2019-05-22 2022-07-21 アジオス ファーマシューティカルズ, インコーポレイテッド N-(4-(4-(シクロプロピルメチル)ピペラジン-1-カルボニル)フェニル)キノリン-8-スルホンアミドの結晶性塩形態

Also Published As

Publication number Publication date
AU2022390088B2 (en) 2026-07-02
WO2023091414A1 (en) 2023-05-25
AU2022390088A1 (en) 2024-05-09
KR20240107326A (ko) 2024-07-09
CA3236880A1 (en) 2023-05-25
MX2024005852A (es) 2024-05-28
JP2024543345A (ja) 2024-11-21
US20250108049A1 (en) 2025-04-03
EP4433057A1 (en) 2024-09-25
IL312679A (en) 2024-07-01
TW202329935A (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
UY37847A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
CL2022003000A1 (es) Compuestos útiles para inhibir la quinasa ret
CR20220584A (es) Inhibidores de kras tricíclicos fusionados
BR112022010112A2 (pt) Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica
CO2022004286A2 (es) Inhibidor de diacilglicerol aciltransferasa 2
CO2018011550A2 (es) Compuestos de pirrolotriazina como inhibidores de tam
BR112022012195A2 (pt) Derivados de piperidina bicíclico substituídos úteis como ativadores de células t
AR126251A1 (es) Inhibidores de cdk2
BR112023026538A2 (pt) Pirazóis com pirimidinil substituído como inibidores de cdk2
CL2022000093A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
BR112023015721A2 (pt) Derivados tricíclicos úteis como inibidores de parp7
PY1983118A (es) Inhibidores de pde4 que contienen boro
MX2024015648A (es) Compuestos como inhibidores de axl
PY1978496A (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
MX389378B (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
BR112019003710A2 (pt) inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7.
CL2025001917A1 (es) Compuestos lipídicos y composiciones de nanopartículas lipídicas
CL2023003979A1 (es) Inhibidores de las transglutaminasas
CL2019000662A1 (es) Inhibidores de dopamina–b–hidroxilasa.
DOP2025000046A (es) Inhibidores de topoisomerasa-1 derivados de exatecán composiciones farmacéuticas y sus usos
CO2024010726A2 (es) Compuestos heterocíclicos y métodos de uso
BR112023004550A2 (pt) Compostos tricíclicos substituídos
ECSP24007534A (es) Inhibidores de transglutaminasas
MX2024005852A (es) Compuestos para tratar anemias asociadas a mds y otras afecciones.